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The human, bovine, murine and rat interferon (IFN)-~t families contain 4 conserved cysteines located at positions 1, 29, 
99 and 139 that are involved in disulfide bridges. Rat and murine IFN-~t subspecies carry a fifth Cys (Cys-86) which 
is not conserved in bovine and human IFN-ct subspecies xcept for human IFN-cfi. Changing Cys-86 in rat IFN-cq into 
Ser or Tyr virtually abolished antiviral activity. As shown by others, the substitution ofCys-86 to Ser in human IFN-cq 
had no pronounced effect on activity. This suggests hat in contrast to human and bovine IFN-~t, Cys-86 in rodent IFN-ct 
plays a crucial role in receptor binding. Changing Cys-I to Gly in rat IFN-cq also destroyed activity, in agreement with 
results obtained in the human IFN-cq system. 
Interferon-cq; Antiviral activity; Disulfide bridge; Interferon receptor; (Rat) 
1. INTRODUCTION 
The interferon (IFN)-ce genes constitute a true 
multigene family [1] that code for proteins that 
show on average 60°70 interspecies homology [2]. 
For instance, all human [1], bovine [2], murine 
[3-5] and rat IFN-oe [6] proteins carry four cys- 
teines at position 1, 29, 99 and 139. Cys-1 and 99 
as well as Cys-29 and 139 are connected by disul- 
fide bonds (Cys-1 is the first amino acid of the 
mature IFN-a peptide) [7]. 
Interestingly, all murine IFN-ce genes and the 
only sequenced rat IFN-a gene (eel) contain a fifth 
Cys at position 86. However, all bovine IFN-tr pro- 
teins carry Arg or Gly and all human IFN-tr 
subspecies (about 15) with one exception carry Ser 
or Tyr at this position. The exception is human 
IFN-ce~ which also contains a Cys at position 86 
[8]. Here, we assess the importance of Cys-86 in rat 
IFN-oq for antiviral activity by substituting this 
amino acid by Tyr or Ser. In addition, we changed 
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Cys-1 to Gly. All mutants are severely affected in 
biological activity. Comparison with mutations 
obtained by Beilharz et al. [9] in the human IFN-ce~ 
protein suggests that Cys-86 is essential for recog- 
nition of the receptor protein in the rat but not in 
humans. 
2. MATERIALS AND METHODS 
2.1. Bacterial strains and growth conditions 
Escherichia coli K-12 strain M5219 was used in all experi- 
ments [10]. This strain harbors a defective and nonexcisable A 
prophage xpressing the clts857 gene and the gene for the an- 
titermination factor N. Bacteria were grown in LC medium 
which contained (per 1) 10 g tryptone, 5g yeast extract (Difco), 
8 g NaCI and 5 ml of 1 M Tris (pH 7.3). Cells were grown at 
28°C to an A650 value of 0.2 and then induced at 42°C for 
120 min. 
2.2. Construction of mutants of rat IFN-al 
The sequence encoding mature rat IFN-trl was cloned in E. 
coli expression vector pIF.D [11], which is derived from 
pPLc236 [10]. pIF.D contains a synthetic ribosomal binding site 
that adds a methionine to the N-terminus of mature IFN-oel. 
Clones pIF.Ser-86 and pIF.Tyr-86 were obtained by site- 
directed mutagenesis of clone pIF.D essentially as described by 
Kunkel [12] and a mixture of two mutagenic heptadecamers. 
Clone pIF.Gly-1 was obtained as a gene fusion where the first 
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four nucleotides of the bacteriophage MS2 coat gene [13] are 
connected to the second nucleotide of the mature IFN-a~ se- 
quence. This yields a product identical to our wild-type xcept 
for the Cys-1 ---* Gly substitution. 
2.3. Rat IFN-crl activity assay 
Bacterial lysates were prepared by suspending the bacteria in 
6 M guanidine HCI, 1% ~'-mercaptoethanol. After centrifuga- 
tion, the supernatant was isolated and tested for antiviral activi- 
ty on RATEC cells as in [14]. The protein yields from the 
different plasmids were compared in Western blots [15] but did 
not differ significantly from one another (not shown). 
3. RESULTS AND DISCUSSION 
The mature rat IFN-o~I sequence containing the 
5 Cys residues is schematically represented in 
f ig. la.  Cys-86 was mutated into either Ser 
(pIF.Ser-86) or Tyr (pIF.Tyr-86) (f ig. lb). These 
clones were assayed for antiviral activity on rat 
cells and the results are listed in table 1. IFN.Ser-86 
has only 10%0 of the activity of the wild-type pro- 
tein and IFN-Tyr-86 even less, if any, antiviral ac- 
tivity. The Ser-86 mutat ion in the human IFN-oll 
gene still yields 40% activity [9]. Since Cys-86 is 
(a) 
1 29 86 99 139 
GIy Set. Tyr 
(b) 
B6 
S F C N O amino acids 
• .TCA TTC TGT AAT GAC.. wild-type 
TCT plF.Ser-86 
TAT pIF.Tyr-86 
I 
C O L P H amino acids 
• .TGT GAC CTG CCT CAT.. wild-type 
GGT plF.Gly-I 
Fig.1. (a) Schematic representation f mature rat IFN-oq. The 
position of the cysteine residues in the protein is shown by their 
amino acid number. The proposed isulfide bonds are indicated 
by connecting lines. Mutations discussed insection 3are shown. 
(b) Relevant nucleotide and amino acid sequence of clones 
pIF.Ser-86, pIF.Tyr-86 and pIF.Gly-l. 
Table 1 
Specific activities of rat and human mutant IFNootl 
Human Rat Rat IFN-cr~ 
IFN-crl a IFN-crl b activity 
(O7o) (%) (u/l)  
Wild-type 100 100 8.4 × 105 
Ser-86 39 10 8.1 × 104 
Tyr-86 n.c. ~ 1 ~9.8 × 103 
Ser-1 5 n.c. - 
Gly-1 n.c. 2 1.6 x 104 
a Tested on human cells (HEp-2) [9]. b Tested on rat cells 
(RATEC). See section 2 and [14]. n.c., not constructed 
not known to be involved in a disulfide bond,  this 
indicates that this residue might be crucial for 
direct recognition of the rat IFN-a l  cell-surface 
receptor, whereas in humans the receptor-protein 
interaction appears less stringent at this particular 
position. These results agree with those obtained 
by Weber et al. [17] who used hybrids between 
human IFN-a~ and human IFN-tw2 to locate 
regions that are important for antiviral activity on 
human,  murine and bovine cells. Hybrids that con- 
tained Tyr at posit ion 86 showed about 20-fold 
reduced specific activity on murine cells, whereas 
activity on human and bovine cells was unchanged. 
The fact that amino acid 86 is variable in human 
and bovine IFN-cr also suggests this residue to be 
relatively unimportant .  
We have also substituted Cys-1 for Gly-1 
(fig. lb). In agreement with the findings for similar 
changes in human IFN-~rl [9], this mutat ion almost 
completely inactivated rat IFN-cr~ (table 1). 
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